Market Place
Sourcing Support
Oligomerix Publishes Data on Novel Small Molecule Therapeutic in Development for Alzheimer’s Disease
09 Aug 2023 //
BUSINESSWIRE
Oligomerix Announces Dosing of Tau Self-Association Inhibitor OLX-07010
02 Feb 2023 //
BUSINESSWIRE
Oligomerix Presents Data from IND-Enabling Studies on Clinical (CTAD)
30 Nov 2022 //
BUSINESSWIRE
Oligomerix receives NIH grant for Phase Ia Alzheimer’s disease study
10 Aug 2022 //
CLINICAL TRIALS ARENA
Oligomerix Awarded $3.35M from NIH to Support Clinical Development
09 Aug 2022 //
BUSINESSWIRE
Oligomerix Announces Key Organizational Changes
20 Jul 2022 //
BUSINESSWIRE
Oligomerix Announces Series B Extension Raise of $2.7M to Support PI Development
02 Jun 2022 //
BUSINESSWIRE
Oligomerix Presents Data on Lead Program at (CTAD) Conference
09 Nov 2021 //
BUSINESSWIRE
Oligomerix Announces Late-Breaking Presentation at 2021 Clinical Trials
02 Nov 2021 //
BUSINESSWIRE
Oligomerix Presents Data on the Efficacy Targeting Tau in Models of AD
30 Jul 2021 //
BUSINESS WIRE
Oligomerix to Present at Alzheimer`s Association International Conference
26 Jul 2021 //
BUSINESSWIRE
Oligomerix Appoints Chief Medical Officer William Erhardt
15 Jul 2021 //
BUSINESS WIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.